Syn2bio S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2025-08-07
Share capital
4,364,564.50 PLN
Activity description

Syn2bio is a company focused on research and development of innovative pharmaceuticals, specifically working on a cardiomarker project and new pharmaceutical molecules. It conducts preclinical and clinical studies, registration, and commercialization of these medical products, including a novel radiopharmaceutical for diagnosing heart diseases.

Registered address
ul. Józefa Piusa Dziekońskiego 3, 00-728 Warszawa, Poland
Website
Email
Phone
Electronic delivery address
AE:PL-49118-21422-FHVGV-18

Financials

Filing timeliness

The financial statement for 2025 was filed on time and audited by a statutory auditor.

  • 202501/12/2025
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 59.38
-2.44 (-3.95%)
59.0060.0061.0062.0059.3810:0012:0014:0016:00
Open
PLN 62.60
High
PLN 62.60
Low
PLN 58.60
Volume
21.75K
Avg. vol.
14.82K
Market cap
PLN 518.34M
P/E ratio
–
EPS
-PLN 1.08
Shares outstanding
8.73M
52-week
PLN 57.10 – 65.78
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026–USD -3.07mUSD -2.54m
Q1 2026–––
Q3 2025–––

Results:Dec 3, 2026

Offer

  • Research and development of radiopharmaceuticals
  • Radiopharmaceutical for diagnosing heart diseases
  • Cardiac tracer
Certifications: GMP

Websites

The site is available in: Polish and English.

  • syn2bio.plSyn2bio – Innowacyjne projekty B+R dla radiofarmacji
    WordPressGoogle Tag ManagerPolylangApache

Trademarks

The company currently holds no active trademarks with the Polish Patent Office. 1 application is pending. The first mark was filed in 2025.

MarkNumberClassesStatusProtected until
syn²bio (word)Z.5927895, 9, 10, 37, 42Application pending –
MarkProtected until
syn²bio (word)–

Authorized Representatives

Anna Urszula Szymańska age 63 – Management Board Member
Cezary Dariusz Kozanecki age 66 – President of the Management Board

Manner of representation

If the management board is a multi-member management board, the President of the Management Board independently, or two members of the management board acting jointly, or one member of the management board jointly with a commercial proxy, are authorized to submit declarations of will on behalf of the company.

Supervisory board

Piotr Stanisław Chudzik age 62 – Supervisory Board Member
Mariusz Wojciech Książek age 54 – Supervisory Board Member
Wiesław Tadeusz Łatała age 60 – Supervisory Board Member
Robert Pikus age 43 – Supervisory Board Member
Sawa Zuzanna Zarębińska age 61 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2025-10-15.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Jun 30, 2026Call to creditors

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name
Roche Polska sp. z o.o.
Aslab Science P.S.A.
Nanogroup S.A.
Bioresearch Group sp. z o.o.
CTI Clinical Trial and Consulting Services Poland sp. z o.o.
Medicofarma Biotech S.A.
Genelytica sp. z o.o.
Orphinic Scientific S.A.
Purevidence sp. z o.o.
Nanothea S.A.

Change history

DateEvent
2026-03-27Share capital increase
2025-08-07Entered in the register

FAQ

Last updated: 2026-04-04